NXP900

NXP900 clinical safety, PKPD and CYP450 interactions (ENA 2025)
NXP900 inhibits tumor growth in FAT1 mutated xenograft models (ENA 2025)
Overcoming osimertinib resistance in NSCLC with NXP900 (AACR 2025)
NXP900 as single agent and in combination with ALK inhibitors in ALK resistant NSCLC models (AACR 2025)
NXP900 blocks YAP1 signaling in NSCLC cell lines (AACR 2025)
First in human phase 1 trial of NXP900 in patients with advanced solid tumors
(AACR 2025)
A Fast Method to Monitor Tyrosine Kinase Inhibitor Mechanisms
(Journal of Med. Chem. 2024)
NXP900 demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines (ENA 2024)
A multi-omics approach to identify biomarkers of response to NXP900 (ENA 2024)
NXP900 demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors (AACR 2024)
NXP900 inhibits YAP1 nuclear localization and tumor growth in esophageal squamous cancers
(ENA 2023)
Differences in target inhibition and anticancer efficacy between NXP900 and dasatinib
(AACR 2023)
Macrophages promote anti-androgen resistance in prostate cancer bone disease
(Journal of Exp. Med. 2023)
Screening of NXP900 and dasatinib identifies differences in their antiproliferative activity (ENA 2022)
Uncovering the molecular mechanisms which predict sensitivity to NXP900
(AACR 2022)
Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors
(Cancer Res. 2021)
A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability
(Cancer Res. 2021)